Enhanced therapeutic efficacy for glioblastoma immunotherapy with an oncolytic herpes simplex virus armed with anti-PD-1 antibody and IL-12

Glioblastoma is the most common and aggressive malignant brain tumor and has limited treatment options. Hence, innovative approaches are urgently needed. Oncolytic virus therapy is emerging as a promising modality for cancer treatment due to its tumor-specific targeting and immune-stimulatory proper...

Full description

Bibliographic Details

Published in:	Molecular Therapy: Oncology
Main Authors:	Lei Wang, Xusha Zhou, Xiaoqing Chen, Yuanyuan Liu, Yue Huang, Yuan Cheng, Peigen Ren, Jing Zhao, Grace Guoying Zhou
Format:	Article
Language:	English
Published:	Elsevier 2024-06-01
Subjects:	glioblastoma GBM oncolytic herpes simplex virus oHSV immunotherapy IL-12
Online Access:	http://www.sciencedirect.com/science/article/pii/S2950329924000419